Newron delays schizophrenia drug trial after FDA raises concerns

Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs.